58 related articles for article (PubMed ID: 38627873)
1. COVID-19 in Lung Transplant Recipients: A Report on 10 Recent Cases.
Reemann L; Kneidinger N; Sczepanski B; Koczulla AR
Viruses; 2024 Apr; 16(5):. PubMed ID: 38793590
[TBL] [Abstract][Full Text] [Related]
2. The Short and Long of COVID-19: A Review of Acute and Chronic Radiologic Pulmonary Manifestations of SARS-2-CoV and Their Clinical Significance.
Simpson S; Hershman M; Nachiappan AC; Raptis C; Hammer MM
Clin Chest Med; 2024 Jun; 45(2):383-403. PubMed ID: 38816095
[TBL] [Abstract][Full Text] [Related]
3. [Correlation between comorbidities and thoracic CT manifestations of COVID-19 pneumonia].
Nadem Boueini N; Haage P; Abanador-Kamper N; Kamper L
Med Klin Intensivmed Notfmed; 2024 Jun; 119(5):384-390. PubMed ID: 37747481
[TBL] [Abstract][Full Text] [Related]
4. Immunocompromised Host Pneumonia: Definitions and Diagnostic Criteria: An Official American Thoracic Society Workshop Report.
Cheng GS; Crothers K; Aliberti S; Bergeron A; Boeckh M; Chien JW; Cilloniz C; Cohen K; Dean N; Dela Cruz CS; Dickson RP; Greninger AL; Hage CA; Hohl TM; Holland SM; Jones BE; Keane J; Metersky M; Miller R; Puel A; Ramirez J; Restrepo MI; Sheshadri A; Staitieh B; Tarrand J; Winthrop KL; Wunderink RG; Evans SE
Ann Am Thorac Soc; 2023 Mar; 20(3):341-353. PubMed ID: 36856712
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of carrimycin in ten patients with severe pneumonia following solid organ transplantation.
Cui XQ; Zhang LW; Zhao P; Feng JJ
World J Clin Cases; 2024 May; 12(15):2542-2550. PubMed ID: 38817218
[TBL] [Abstract][Full Text] [Related]
6. Protracted course of SARS-CoV-2 pneumonia in moderately to severely immunocompromised patients.
Lee J; Kim AR; Kang SW; Chang E; Bae S; Jung J; Kim MJ; Chong YP; Lee SO; Choi SH; Kim YS; Kim SH
Clin Exp Med; 2023 Oct; 23(6):2255-2264. PubMed ID: 36607462
[TBL] [Abstract][Full Text] [Related]
7. Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review.
Galmiche S; Luong Nguyen LB; Tartour E; de Lamballerie X; Wittkop L; Loubet P; Launay O
Clin Microbiol Infect; 2022 Feb; 28(2):163-177. PubMed ID: 35020589
[TBL] [Abstract][Full Text] [Related]
8. Clinical and Imaging Characteristics of SARS-CoV-2 Breakthrough Infection in Hospitalized Immunocompromised Patients.
Lee JE; Kim J; Hwang M; Kim YH; Chung MJ; Jeong WG; Jeong YJ
Korean J Radiol; 2024 May; 25(5):481-492. PubMed ID: 38627873
[TBL] [Abstract][Full Text] [Related]
9. Association of COVID-19 Vaccination With Breakthrough Infections and Complications in Patients With Cancer.
Gong IY; Vijenthira A; Powis M; Calzavara A; Patrikar A; Sutradhar R; Hicks LK; Wilton D; Singh S; Krzyzanowska MK; Cheung MC
JAMA Oncol; 2023 Mar; 9(3):386-394. PubMed ID: 36580318
[TBL] [Abstract][Full Text] [Related]
10. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of COVID-19 Vaccines Over Time Against Clinical and Radiologic Outcomes Related to Severe SARS-CoV-2 Infection.
Lee JE; Jin KN; Hong H; Jeong YJ; Yoon SH
Radiology; 2024 Jan; 310(1):e231928. PubMed ID: 38259210
[TBL] [Abstract][Full Text] [Related]
12. Association Between Immune Dysfunction and COVID-19 Breakthrough Infection After SARS-CoV-2 Vaccination in the US.
Sun J; Zheng Q; Madhira V; Olex AL; Anzalone AJ; Vinson A; Singh JA; French E; Abraham AG; Mathew J; Safdar N; Agarwal G; Fitzgerald KC; Singh N; Topaloglu U; Chute CG; Mannon RB; Kirk GD; Patel RC;
JAMA Intern Med; 2022 Feb; 182(2):153-162. PubMed ID: 34962505
[TBL] [Abstract][Full Text] [Related]
13. Imaging and Clinical Features of COVID-19 Breakthrough Infections: A Multicenter Study.
Lee JE; Hwang M; Kim YH; Chung MJ; Sim BH; Chae KJ; Yoo JY; Jeong YJ
Radiology; 2022 Jun; 303(3):682-692. PubMed ID: 35103535
[TBL] [Abstract][Full Text] [Related]
14. Estimation of COVID-19 mRNA Vaccine Effectiveness and COVID-19 Illness and Severity by Vaccination Status During Omicron BA.4 and BA.5 Sublineage Periods.
Link-Gelles R; Levy ME; Natarajan K; Reese SE; Naleway AL; Grannis SJ; Klein NP; DeSilva MB; Ong TC; Gaglani M; Hartmann E; Dickerson M; Stenehjem E; Kharbanda AB; Han J; Spark TL; Irving SA; Dixon BE; Zerbo O; McEvoy CE; Rao S; Raiyani C; Sloan-Aagard C; Patel P; Dascomb K; Uhlemann AC; Dunne MM; Fadel WF; Lewis N; Barron MA; Murthy K; Nanez J; Griggs EP; Grisel N; Annavajhala MK; Akinseye A; Valvi NR; Goddard K; Mamawala M; Arndorfer J; Yang DH; Embí PJ; Fireman B; Ball SW; Tenforde MW
JAMA Netw Open; 2023 Mar; 6(3):e232598. PubMed ID: 36920396
[TBL] [Abstract][Full Text] [Related]
15. COVID-19 hospitalisations in immunocompromised individuals in the Omicron era: a population-based observational study using surveillance data in British Columbia, Canada.
Bahremand T; Yao JA; Mill C; Piszczek J; Grant JM; Smolina K
Lancet Reg Health Am; 2023 Apr; 20():100461. PubMed ID: 36890850
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
